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CD10, and MUM1/IRF4 did not correlate with prognosis. CONCLUSION The findings are limited by
the fact that only 23% of all G-PCNSL-SG1 patients could be included in the analysis. If validated in
an independent cohort, BCL6 may assume clinical relevance as an unfavorable prognostic biomarker in
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Abstract 
Background: We investigated the prognostic significance of B cell differentiation status and 
common B cell differentiation markers in a post hoc analysis of 119 patients with primary 
CNS lymphoma (PCNSL) homogenously treated with high-dose methotrexate (HDMTX)-
based chemotherapy within the prospective G-PCNSL-SG1 trial. Methods: Protein 
expression of BCL-2, BCL-6, CD10 and MUM-1/IRF-4 was evaluated by 
immunohistochemistry, and the association with survival was analyzed. Results: The median 
follow-up of all patients was 67.5 months. The median progression-free survival (PFS) was 
10.61 (95% CI 4.23-17.00) months; the median overall survival (OS) was 28.85 (95% CI 
17.96-39.73) months. Eighty-nine tumors expressed BCL-2 (92.7%), 24 (20.5%) CD10, 60 
(54.1%) BCL-6 and 87 (79.0%) MUM-1/IRF-4. On the basis of the Hans algorithm, 80 
(73.4%) tumors were classified to the non-GCB group suggesting a post germinal center 
origin of PCNSL. BCL-6 expression (cut-off point 30%), but none of the other markers, was 
associated with shorter PFS (P=0.047) and OS (P=0.035). On multivariate analysis BCL-6 
expression was associated with shorter PFS (HR 1.95, 95% CI 1.22-3.12, P=0.005) but not 
OS (HR 1.85, 95% CI 0.71-4.80, P=0.21).  Classification according to Hans algorithm and 
expression status of single B cell markers BCL-2, CD10 and MUM-1/IRF-4 did not correlate 
with prognosis. Conclusion: The findings are limited by the fact that only 23% of all G-
PCNSL-SG1 patients could be included in the analysis. If validated in an independent cohort, 
BCL-6 may assume clinical relevance as an unfavorable prognostic biomarker in PCNSL. 
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Introduction 
Primary CNS lymphoma (PCNSL) is a rare aggressive B cell neoplasia most frequently of 
diffuse large B cell lymphoma type (DLBCL) that is confined to the CNS at time of 
diagnosis1.  The formerly poor prognosis of PCNSL has been greatly improved by systemic 
high-dose methotrexate (HDMTX)-based polychemotherapy which provides the current 
standard treatment for all patients with PCNSL. Despite substantial improvements in the 
treatment of PCNSL the response to HDMTX-based chemotherapy is quite heterogeneous 
and overall prognosis remains poor with a median progression-free survival (PFS) of 
approximately 12 months and a median overall survival (OS) of about 3 years in most studies. 
This necessitates the identification and evaluation of reliable predictive and prognostic 
biomarkers for risk-stratified treatment decisions2.   
In systemic DLBCL, prognostic value of different biologic markers has widely been studied. 
Moreover, at least two prognostically important subgroups (germinal center B cell-like [GCB] 
and activated B cell-like [ABC] DLBCL) were characterized by gene expression profiling 
(GEP) using cDNA microarray3,4. Due to impracticability to perform microarray analysis on 
every patient, various immunohistochemical algorithms have been subsequently developed to 
capture the molecular diversity and stratify patients according to survival5-8. The most widely 
used method is the Hans algorithm separating DLBCL into germinal-center B cell (GCB) and 
non-germinal-center B cell (non-GCB) groups by using antibodies against CD10, BCL-6 and 
MUM-1/IRF-49. In PCNSL, a few small and mostly retrospective studies either failed to 
observe a prognostic impact of common B cell differentiation markers or revealed 
contradictory results10-14. Here, we present the analysis of a set of B cell differentiation 
markers and their prognostic impact in a cohort from G-PCNSL-SG-1, the largest trial ever 
conducted in PCNSL.  
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Materials and Methods: 
Patients and treatment  
Immunocompetent adult patients with newly diagnosed PCNSL included in the G-PCNSL-
SG1 trial with tumor samples available at one of the two reference pathology centers and 
tumor amount sufficient for immunohistochemical analysis were included. The inclusion and 
exclusion criteria were reported previously15. Patients were randomly allocated to receive 
first-line HDMTX-based chemotherapy with or without subsequent whole-brain radiotherapy 
(WBRT). Between May 2000 and August 2006, study therapy consisted of HDMTX (4 g/m2 
as a 4-h i.v. infusion with dose reduction according to creatinine clearence) on day 1 of six 
14-day cycles; thereafter, patients were to receive HDMTX plus ifosfamide (1.5 g/m2) on 
days 3–5 of six 14-day cycles. In those assigned to receive first-line chemotherapy followed 
by radiotherapy, WBRT was to be given at a total dose of 45 Gy in 1.5 Gy fractions. Patients 
allocated to first-line chemotherapy without WBRT who had not achieved complete response 
(CR) to HDMTX-based chemotherapy were given high-dose cytarabine (HDAraC; 2 × 3 g/m2 
on days 1–2 of 22-day cycles). 
The study protocol was approved by local institutional review boards or ethics committees. 
All participants gave written informed consent. 
 
Immunohistochemical analysis  
Immunostaining on paraffin sections was performed centrally at two study reference 
pathology centers for CD10 (clone 56C6, Leica Biosystems, Newcastle upon Tyne, UK), 
BCL-6 (clone LN22, Leica Biosystems; clone PG-B6p, Dako, Hamburg, Germany), BCL-2 
(clone100/D5 Leica Biosystems; clone 124, Dako) and MUM-1/IRF-4 (clone MUM1p, 
DAKO) using an automated immunostainer (BondMax™, Leica Biosystems; Benchmark XT, 
Roche-Ventana, Mannheim, Germany). Antigen retrieval was performed using appropriate 
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conditions, bound antibodies were made visible employing Bond Polymer Refine DAB, or 
ultraView Universal DAB detection kit (Roche-Ventana), developed and counterstained using 
the manufacturer´s protocols and reagents.  
Immunohistological labeling of BCL-2, CD10, BCL-6 and MUM-1/IRF-4 was visually 
analyzed and interpreted according to the methods and cut-off points previously published by 
Horn et al.16. For BCL-6 staining, tumors with more than 30% positively labeled cells were 
considered positive. Tumors were further classified to GCB and non-GCB subgroups 
according to their expression of CD10, BCL-6 and MUM-1/IRF-4 using the methods and cut-
off points (>30%) published by Hans et al.9. Tumors with CD10 expression, or BCL-6 
expression without expression of MUM-1/IRF-4 were defined as GCB. The remaining tumors 
were classified as non-GCB. 
 
Statistics  
Progression-free survival (PFS) was defined as the time from study entry to first progression 
or death from any cause. Overall survival (OS) was defined as the time from study entry to 
death. PFS and OS were estimated by the Kaplan–Meier method. Group comparisons were 
carried out using the log-rank test. Additionally, simple and multiple Cox proportional hazard 
regression models were calculated, hazard ratios including two-sided 95% limits of 
confidence were calculated. The variables included in the multiple Cox models were 
determined by forward and backward variable selection leading to identical models. Non-
significant variables were not included in the final models. Distribution of patients’ 
characteristics to different groups was analyzed by the chi-square test. Mean values of 
independent groups were compared with Student’s t-test. The level of significance was 0.05 
(two-sided). Commercially available software was used (SPSS for Window, release 21.0). 
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Results: 
Patient characteristics and clinical outcome 
As central collection of tumor tissue was not intended at time of study enrolment, all available 
tumor material from participating centers were collected. Of 526 eligible patients treated 
within the G-PCNSL-SG1 trial, sufficient tumor material of 119 patients were available for 
the present immunohistochemical analysis. The main patient characteristics, treatment and 
outcome are summarized in Table 1. With exception of multifocal brain involvement and type 
of initial surgery for PCNSL patient characteristics were comparable to those of study patients 
not included in this analysis (Supplementary Table 1). However, there was a non-significant 
trend to better PFS (P=0.057) and OS (P=0.056) in patients included in our IHC analyses. 
The median follow-up of all patients studied here was 67.5 months. The median PFS was 10.6 
months (95% CI 4.2-17.00), the median OS was 28.9 months (95% CI 18-39.7).  
 
Immunohistochemical profiles 
Eighty-nine of 96 tumors (92.7%) expressed BCL-2 and 24 of 117 (20.5%) CD10. BCL-6 and 
MUM-1/IRF-4 were expressed in 60 of 111 (54.1%) and 87 of 110 (79.0%) tumors, 
respectively. Fifty-three tumors of the BCL-6-positive tumors co-expressed MUM-1/IRF-4 
(88.3%). Twenty-nine tumors (26.6%) were classified as GCB and 80 (73.4%) as non-GCB 
group. 
 
Prognostic analysis 
Among the biologic markers, only BCL-6 expression correlated with shorter PFS and OS: 
P=0.047 and P=0.035, respectively (Fig. 1). On univariate analysis, the association of BCL-6 
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was significant for both PFS (HR 1.53, P=0.047, 95% CI 1.01-2.34) and OS (HR 1.66, 
P=0.035, 95% CI 1.04-2.65). On multivariate analysis, however, a significant association with 
PFS only was found: HR 1.95, P=0.005, 95% CI 1.22-3.12 (Table 2). All other biologic 
markers tested did not correlate with outcome. Particularly, classification according to the 
Hans algorithm revealed no significant difference between GCB and non-GCB subgroups 
with respect to survival outcome.  
Patient characteristics and response to treatment did not differ between BCL-6-positive and -
negative patients except for number of brain lesions (Supplementary Table 2) with BCL-6 
expression significantly being associated with multifocal brain involvement (BCL-6-positive: 
33.3% vs BCL-6-negative: 15.7%). 
When the impact of commonly accepted clinical risk factors in PCNSL was tested, a 
significant association of age (HR 1.027, P=0.026, 95% CI 1.003-1.05) and Karnofsky 
Performance score (KPS) (HR 0.99, P=0.044, 95% CI 0.97-1.00) with OS was found on 
univariate analysis. The MSKCC score, which is deduced from age and KPS, showed a 
prognostic association with both PFS and OS in multivariate analyses (PFS: HR 1.87, 
P=0.011, 95% CI 1.15-3.04; OS: HR 2.95, P=0.016, 95% CI 1.22-7.13). Multifocal brain 
involvement was significantly associated with shorter PFS (HR 1.79, P=0.011, 95% CI 1.14-
2.80) on univariate and shorter OS (HR 2.72, P=0.019, 95% CI 1.18-6.28) on multivariate 
analysis. To exclude that the effect of multifocal disease has been due to confounding with the 
type of surgery we performed adjusted and stratified analysis for these two factors for OS and 
PFS. In both adjusted analyses, multifocal disease remained significant after inclusion of type 
of surgery: PFS odds ratio = 1.78, P=0.012; OS odds ratio = 2.77, P=0.012. Within cases with 
resection, the odds ratio for PFS was 2.06; P= 0.043 and for OS 2.13; P=0.23; within cases 
with biopsy the odds ratio for PFS was 1.58; P= 0.131 and for OS 2.97; P=0.044 (the lack of 
significance in some subgroups was most probably due to their small size). 
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Discussion 
Our data confirm previous studies indicating an activated B cell like immunophenotype and 
post-GC origin of most PCNSL12,17-19 with frequent expression of the activation marker 
MUM-1/IRF-4, infrequent CD10 expression and expression of BCL-6, a marker of germinal 
center, in approx. half of the cases. In normal B cells, BCL-6 and MUM-1/IRF-4 are 
exclusively expressed20 and high percentage of BCL-6/MUM-1/IRF-4 co-expression has been 
shown to be a characteristic feature of PCNSL as compared to systemic DLBCL9,12,21-23. 
Confirming previous analyses, a vast majority of our BCL-6-positive tumors co-expressed 
MUM-1/IRF-4 which indicates the activated immunophenotype of PCNSL12,21. Additionally, 
most PCNSL of our series belonged to the non-GCB group on the basis of the Hans 
algorithm, which is in accordance with earlier immunohistochemical analyses12,17-19 and GEP 
analysis of 21 PCNSL cases24.  
The prognostic utility of B cell differentiation status and various B cell differentiation markers 
to predict outcome in PCNSL patients is currently questionable. The available data 
concerning this issue are based on mostly retrospective studies with small patient numbers 
and heterogeneous treatment schedules10-14,18,19,21,25,26. We here investigated expression and 
prognostic significance of B cell differentiation markers in the so far largest cohort of PCNSL 
patients homogenously treated with HDMTX-based chemotherapy within the prospective G-
PCNSL-SG1 trial. BCL-2 as an antiapoptotic protein and normally down-regulated in 
germinal center B cells has been shown to be an independent poor prognostic indicator for 
systemic DLBCL27,28. In our series, we did not observe a correlation of BCL-2 expression 
with PFS or OS. Considering the low frequency of BCL-2-negative PCNSL, BCL-2 
expression seems to be more a characteristic then a prognostic feature in PCNSL. The 
expression status of single B cell markers CD10 and MUM-1/IRF-4 also did not correlate 
with prognosis which is in accordance with previous analyses by Braaten et al. and 
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others12,14,26. However, the percentage of CD10-positive tumors might have been too low 
increasing the potential for confounding variables.   
Previous analyses of the prognostic significance of BCL-6 expression in PCNSL yielded 
controversial results. Lossos et al. reported an independent positive association with PFS (and 
nearly significant with OS), and Braaten et al. found an independent and significant positive 
association with OS13,26. Both were retrospective studies with heterogeneously treated 
patients. Moreover, an unusually low positivity threshold of only 10% was used by Braaten et 
al., resulting in expression frequency of 79%. In contrast, Momota et al. found an 
independent negative association of BCL-6 expression with PFS14. In the only prospective 
multi center trial addressing this question, CALGB 50202, BCL6 expression significantly 
correlated with shorter survival11. Our findings confirm a negative correlation of BCL-6 
expression with outcome in PCNSL. Reasons for discrepancy with other studies could be the 
retrospective nature of previous studies, few patient numbers with consequent limited 
statistical power and possibility of confounding variables, non-uniform treatment and 
different immunophenotype and classification methods among different studies. Interestingly, 
there seems to be a correlation between BCL-6 expression and negative clinical 
characteristics in PCNSL. Camilleri-Broet et al. found an association with higher age and 
worse performance status12. In the present analysis, a correlation between BCL-6 expression 
and multifocal brain involvement was found. Multifocal brain involvement and inferior 
survival outcome was a finding in the whole G-PCNSL-SG1 cohort29, and was also reported 
by others30.   
In our series, we did not observe a significant prognostic difference between the GCB and 
non-GCB subgroups. This is in line with several smaller studies12,14,18,25.  
Our study has several limitations that have to be regarded. Although based on the randomized 
controlled G-PCNSL-SG1 trial, the presented data is a formerly unplanned post hoc analysis 
of only 23% of all G-PCNSL-SG1 patients with an - unintended - positive selection bias for 
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analyzed patients. The bias was due to selection of patients on basis of availability of large 
tumor amount which resulted in higher percentage of patients with <2 tumor lesions and 
consecutively subtotal or total tumor resection. These factors were associated with better 
outcome in the total G-PCNSL-SG1 study population29 and might explain the non-significant, 
but potentially biologically important trend to a superior prognosis in patients included in our 
IHC analyses. It remains unclear how this bias might have impacted our findings. A further 
shortcoming of the study is the number of patients analyzed and the number of events (PFS: 
99, OS: 83). Both, although high as compared to previous studies, might have been too low 
for some outcome differences to become significant, and the multivariate analysis has to be 
interpreted with caution. Even so the selection of variables was identical with forward and 
backward methods a change of values in a small number of patients might have led to 
different models. This may also explain the differences between univariate and multivariate 
analyses for several factors which showed substantially higher odds ratios in multivariate as 
compared to univariate analysis (e.g. MSKCC score and multifocal brain involvement in the 
analysis of OS) .  
Most of our patients (74.7%) were treated with HDMTX alone which was the standard first-
line treatment regimen at time of study initiation. The type of chemotherapy did not have a 
significant prognostic impact in our uni- and multivariate analyses, but the number of patients 
might have been to small. Thus, we cannot exclude that the survival difference between the 
BCL-6-positive and BCL-6-negative group within our investigation could have been due to 
the less effective treatment regimen and therefore might not be applicable for patients 
undergoing an intensified first-line treatment.  
In conclusion, our findings confirm an activated B cell like immunophenotype and post-GC 
origin of PCNSL and indicate BCL-6 expression as a valuable biomarker for inferior 
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prognosis. In view of the fact that several previous studies reported contradicting results, 
further prospective studies are necessary to validate our results. 
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Figure 1: 
Comparison of progression-free survival and overall survival according to BCL-6 expression. 
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Table 1:  
Patient characteristics, treatment and treatment response 
 
 
 
Characteristics All patients 
n=119 
n (%) 
Median age in years 
(range) 63 (26-83) 
Males 62 (52.1%) 
KPS, median 70 
MSKCC score  
1 13 (10.9%) 
2 59 (49.6%) 
3 31 (26.1%) 
No specification 16 (13.4%) 
Serum LDH elevated 23 (19.3%) 
No specification 59 (49.6%) 
Meningeal involvement 6 (5.0%) 
No specification 30 (25.2%) 
No. of cerebral lesions  
0-1 82 (68.9%) 
≥2 lesions 30 (25.2%) 
No specification 7 (5.9%) 
HDMTX versus HDMTX/IFO 89/30 
WBRT 75 (63.0%) 
Response to HDMTX-based chemotherapy  
Complete response 53 (44.5%) 
Partial response 20 (16.8%) 
Stable disease 6 (5.0%) 
Progressive disease 27 (22.7%) 
No specification 13 (10.9%) 
Median PFS in months (95% CI) 10.61 (4.23-17.00) 
Median OS  in months (95% CI) 28.85 (17.96-39.73) 
KPS, Karnofsky Performance Score; MSKCC, Memorial Sloan-Kettering Cancer 
Center; LDH, lactate dehydrogenase, HDMTX, high-dose methotrexate; IFO, 
ifosfamide; WBRT, whole-brain radiotherapy 
Table 2: Univariate and multivariate analyses for PFS and OS 
 Univariate analysis Multivariate analysis 
 Hazard ratio 
P 
value  95% CI 
Hazard 
ratio 
P  
value  95% CI 
PFS       
Age* 1.01 0.32 0.99-1.03 n.d. --- --- 
KPS† 0.99 0.23 0.98-1.01 n.d. --- --- 
Gender# 0.81 0.29 0.54-1.20 0.69 0.108 0.44-1.08 
Multifocal brain involvement◊ 1.79 0.011 1.14-2.80 1.20 0.49 0.71-2.03 
MSKCC score+ 1.40 0.14 0.89-2.20 1.87 0.011 1.15-3.04 
LDH○ 1.27 0.43 0.70-2.28 1.41 0.32 0.72-2.76 
Surgery (biopsy vs. resection) 1.28 0.24 0.85-1.91 0.94 0.80 0.57-1.54 
HDMTX versus HDMTX/IFO 0.99 0.97 0.62-1.58 1.00 1.00 0.60-1.67 
BCL-2‡‡ 1.28 0.60 0.52-3.17 1.09 0.86 0.43-2.77 
BCL-6†† 1.53 0.047 1.01-2.34 1.95 0.005 1.22-3.12 
CD10## 0.81 0.42 0.49-1.34 0.82 0.46 0.47-1.40 
MUM-1/IRF-4** 0.96 0.89 0.58-1.60 0.77 0.37 0.43-1.37 
GCB/non-GCB++ 1.12 0.65 0.70-1.80 1.20 0.49 0.72-2.00 
OS       
Age* 1.027 0.026 1.003-1.05 n.d. --- --- 
KPS† 0.99 0.044 0.97-1.00 n.d. --- --- 
Gender# 0.75 0.20 0.49-1.16 0.48 0.091 0.20-1.13 
Multifocal brain involvement◊ 1.47 0.11 0.91-2.39 2.72 0.019 1.18-6.28 
MSKCC score+  1.66 0.041 1.02-2.70 2.95 0.016 1.22-7.13 
LDH○ 1.10 0.77 0.59-2.05 1.89 0.38 0.46-7.80 
Surgery (biopsy vs. resection) 1.17 0.50 0.75-1.82 0.82 0.67 0.33-2.02 
HDMTX versus HDMTX/IFO 0.92 0.76 0.53-1.60 0.37 0.19 0.084-1.63 
BCL-2‡‡ 0.94 0.89 0.38-2.33 0.68 0.62 0.16-3.01 
BCL-6†† 1.66 0.035 1.04-2.65 1.85 0.21 0.71-4.80 
CD10## 0.61 0.09 0.35-1.07 1.00 1.00 0.39-2.57 
MUM-1/IRF-4** 1.00 0.99 0.57-1.77 2.13 0.32 0.48-9.41 
GCB/non-GCB++ 1.46 0.17 0.86-2.48 1.14 0.79 0.44-2.98 
*Age of 60 years or older versus younger than 60 years. †10% increase in Karnofsky Performance Score. In multivariate 
analyses, age and KPS were not separately but combined analysed as MSKCC score. #Female sex versus male sex. ◊≥2 
lesions versus 0-1 cerebral lesions. +MSKCC score 3 vs. 1/2. ○Elevated serum lactate dehydrogenase (LDH) versus normal. 
‡‡BCL-2 positive versus negative expression. ††BCL-6 positive versus negative expression. ##CD10 positive versus negative 
expression. **MUM-1/IRF-4 positive versus negative expression. ++GCB versus non-GCB according to Hans algorithm.  
 
Supplementary Table 1:  
Comparison of clinical characteristics, treatment and treatment response of patients with and 
without IHC analysis. 
 
Characteristics Patients with IHC 
analysis 
n=119 
n (%) 
Patients without 
IHC analysis 
n=405 
n (%) 
P value  
(with vs. 
without IHC 
analysis) 
Median age in years 
(range) 63 (26-83) 63 (19-84) 0.34 
Males 62 (52.1%) 236 (58.3%) 0.25 
KPS, median 70 70 0.51 
MSKCC score    
1 13 (10.9%) 66 (16.3%) 0.97 
2 59 (49.6%) 165 (40.7%)  
3 31 (26.1%) 119 (29.4%)  
No specification 16 (13.4%) 55 (13.6%)  
Serum LDH elevated 23 (19.3%) 88 (21.7%) 0.09 
No specification 59 (49.6%) 156 (38.5%)  
Meningeal involvement 6 (5.0%) 11 (2.7%) 0.22 
No specification 30 (25.2%) 80 (19.8%)  
No. of cerebral lesions    
0-1 82 (68.9%) 190 (46.9%) 0.002 
≥2 lesions 30 (25.2%) 145 (35.8%)  
No specification 7 (5.9%) 70 (17.3%)  
Type of surgical intervention    
Biopsy 43 (36.1%) 288 (71.1%) <0.001 
Subtotal resection 23 (23.2%) 47 (11.6%)  
Gross total resection 33 (27.7%) 33 (8.1%)  
No specification 20 (16.8%) 37 (9.1%)  
HDMTX versus HDMTX/IFO 89/30 311/94 0.71 
WBRT  75 (63.0%) 202 (49.9%) 0.60 
Response to HDMTX-based chemotherapy    
Complete response 53 (44.5%) 132 (32.5%) 0.111 
Partial response 20 (16.8%) 88 (21.7%)  
Stable disease 6 (5.0%) 16 (4.0%)  
Progressive disease 27 (22.7%) 115 (28.4%)  
No specification 13 (10.9%) 54 (13.3%)  
Median PFS in months (95% CI) 10.61 (4.23-17.00) 6.08 (1.19-7.97) 0.057 
Median OS  in months (95% CI) 28.85 (17.96-39.73) 19.06 (14.87-23.24) 0.056 
KPS, Karnofsky Performance Score; MSKCC, Memorial Sloan-Kettering Cancer Center; LDH, lactate dehydrogenase, 
HDMTX, high-dose methotrexate; IFO, ifosfamide; WBRT, whole-brain radiotherapy 
Supplementary Table 2:  
Comparison of clinical characteristics and outcome of patients according to 
BCL-6 expression status (n=111). 
KPS, Karnofsky Performance Score; MSKCC, Memorial Sloan-Kettering Cancer Center; LDH, 
lactate dehydrogenase, HDMTX, high-dose methotrexate; IFO, ifosfamide; WBRT, whole-brain 
radiotherapy 
 
Characteristics BCL-6+ 
(n=60) 
BCL-6- 
(n=51) 
P value 
(BCL-6+ vs. 
BCL-6-) 
Age (years) 
Median (range) 65.5 (37-81) 63 (26-83) 0.61 
Males 27 (45.0%) 30 (58.8%) 0.183 
KPS, median 70 70 0.97 
MSKCC score  
1 5 (8.3%) 6 (11.8%) 0.73 
2 32 (53.3%) 23 (45.1%)  
3 17 (28.3%) 13 (25.5%)  
No specification 6 (10.0%) 9 (17.6%)  
Serum LDH elevated 11 (18.3%) 9 (17.6%) 0.98 
No specification 30 (50.0%) 25 (49.0%)  
Meningeal involvement 2 (3.3%) 4 (7.8%) 0.40 
No specification 15 (25.0%) 14 (27.4%)  
No. of cerebral lesions  
0-1 37 (61.6%) 40 (78.4%) 0.046 
≥2 lesions 20 (33.3%) 8 (15.7%)  
No specification 3 (5.0%) 3 (5.9%)  
Type of surgical intervention    
Biopsy 33 (55.0%) 23 (45.1%) 0.47 
Subtotal resection 11 (18.3%) 9 (17.6%)  
Gross total resection 15 (25.0%) 18 (35.3%)  
No specification 1 (1.7%) 1 (2.0%)  
HDMTX versus HDMTX/IFO 48/12 34/17 0.132 
WBRT 41 (68.3%) 30 (58.8%) 0.33 
Response to HDMTX-based 
chemotherapy    
Complete response 26 (43.3%) 26 (51.0%) 0.79 
Partial response 10 (16.7%) 7 (13.7%)  
Stable disease 4 (6.7%) 2 (3.9%)  
Progressive disease 14 (23.3%) 10 (19.6%)  
No specification 6 (10.0%) 6 (11.8%)  
Median PFS (months) 8.48  (5.07-11.89) 
20.96  
(8.03-33.92) 0.047 
Median OS (months) 24.87  (20.71-29.03) 
54.11  
(19.71-88.51) 0.035 
